Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip

Jan 04, 2010, 09:17 ET from Reportlinker

NEW YORK, Jan. 4 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biochip Markets: Microarrays and Lab-on-a-Chip

http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html

THIS REPORT:

Contains a global market review of the biochips industry

Describes various biochips including current and potential applications

Offers the current global market status for biochip products, with trends and forecasts for growth through 2014

Addresses technological issues, including the latest advances

Discusses driving forces in the biochip industry, including large-scale integration, research initiatives and drug discovery

Profiles biochip companies while paying attention to industry alliances.

Chapter- 1: INTRODUCTION -- Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

INTENDED AUDIENCE 2

SCOPE OF REPORT 2

METHODOLOGY 3

INFORMATION SOURCES 3

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 4

BCC ONLINE SERVICES 4

DISCLAIMER 4

Chapter-2: SUMMARY

SUMMARY TABLE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, 2007-2014 ($ MILLIONS) 6

SUMMARY (CONTINUED) 7

Chapter-3: OVERVIEW

INTRODUCTION 8

INTRODUCTION (CONTINUED) 9

TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 10

FIGURE 1 EVOLUTION OF BIOCHIPS 10

INTRODUCTION (CONTINUED) 11

BIOCHIP TYPES 12

FIGURE 2 CLASSIFICATION OF BIOCHIPS 12

TABLE 2 COMPARISON OF THE TWO MAJOR BIOCHIP TYPES 13

BIOCHIP TYPES (CONTINUED) 14

TABLE 3 BIOCHIP NOMENCLATURE 15

BIOCHIP TECHNOLOGIES COVERED IN THIS REPORT 16

TABLE 4 SCOPE OF THIS REPORT 16

WHAT IS NEW IN THIS REPORT 16

MARKET POTENTIAL OF BIOCHIPS 17

TABLE 5 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 18

TABLE 6 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS) 18

DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS 19

TABLE 7 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH 20

DRIVING FORCES FOR ... (CONTINUED) 21

BIOCHIPS: A CONVERGENCE OF DIVERSE TECHNOLOGIES 22

TABLE 8 MULTIDISCIPLINARY FIELD OF BIOCHIPS 22

LIFE CYCLE STATUS OF BIOCHIP PRODUCTS 23

TABLE 9 LIFE CYCLE STATUS OF BIOCHIP TYPES 23

COMMERCIAL STATUS OF BIOCHIPS 24

MICROARRAYS 24

LOAC 25

THE BIOCHIP INDUSTRY 25

TABLE 10 BIOCHIP INDUSTRY KEY COMPETITORS 25

THE BIOCHIP INDUSTRY (CONTINUED) 26

Chapter-4: MICROARRAY TECHNOLOGIES

INTRODUCTION 27

THE NANOSCALE WORLD 27

TABLE 11 THE NANOSCALE WORLD 27

TABLE 12 MICROARRAY TYPES 28

TABLE 13 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 28

The Nanoscale World (Continued) 29

DNA MICROARRAY TECHNOLOGIES 30

INTRODUCTION 30

FIGURE 3 MICROARRAY FEATURE DENSITY 30

FIGURE 4 MICROARRAY RESOLUTION 31

TABLE 14 MICROARRAY GENOME CONTENT 31

TABLE 15 DNA MICROARRAY PLATFORM FEATURES 32

TABLE 16 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 33

TABLE 16 (CONTINUED) 34

Introduction (Continued) 35

STEPS IN THE DNA MICROARRAY EXPERIMENT 36

DNA MICROARRAY APPLICATIONS 36

TABLE 17 DNA MICROARRAY APPLICATIONS 37

Gene Expression Profiling 38

TABLE 18 PROBES FOR GENE EXPRESSION DNA MICROARRAYS 38

Gene Expression Profiling (Continued) 39

TABLE 19 EXAMPLE APPLICATIONS OF GENE EXPRESSION PROFILING 40

FIGURE 5 GENETIC ANALYSIS TECHNOLOGY COMPETITIVE SPACE 41

TABLE 20 GENETIC ANALYSIS TECHNOLOGIES COMPARISON 42

FIGURE 6 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1 43

FIGURE 7 COMPETITIVE SPACE FOR GENE EXPRESSION ANALYSIS 44

FIGURE 8 APPLICATIONS SPACE WITH INTENSE TECHNOLOGY COMPETITION 45

Gene Expression Profiling (Continued) 46

TABLE 21 PLATFORMS FOR HIGH-THROUGHPUT QUANTITATIVE GENE EXPRESSION ANALYSIS 47

TABLE 22 GENE EXPRESSION PLATFORMS OF TWO LEADING DNA ARRAY MANUFACTURERS 47

TABLE 22 (CONTINUED) 48

TABLE 23 PROBE SENSITIVITY AND SPECIFICITY 48

Gene Expression Profiling (Continued) 49

SNP Analysis 50

FIGURE 9 SNP ANALYSIS PLATFORMS 51

Epigenetic Analysis 52

FIGURE 10 EPIGENOMICS WITHIN THE MOLECULAR BIOLOGY PARADIGM 53

DNA Methylation 53

FIGURE 11 EPIGENETIC CHANGES TO DNA AFFECT GENE EXPRESSION 54

Histones 54

FIGURE 12 HISTONE TAIL REGIONS MODIFIED BY HAT AND HDAC 55

DNA Methylation and Histone Analysis Workflow 56

FIGURE 13 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS 57

DNA Methylation Microarrays 57

ChIP-on-Chip 58

TABLE 24 CHIP ASSAYS 59

TABLE 25 TECHNOLOGIES FOR MAPPING GENOMIC LOCATION OF CHROMATIN PROTEINS AND ENZYMES 60

TABLE 26 PLATFORMS FOR HIGH DENSITY OLIGONUCLEOTIDE EPIGENETICS ARRAYS 61

Cytogenetic Analysis 61

TABLE 27 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES 62

FIGURE 14 COMPETITIVE SPACE FOR CNV ANALYSIS 63

Cytogenetic Analysis (Continued) 64

TABLE 28 CGH MICROARRAY PROBE PLATFORMS 65

TABLE 29 CGH MICROARRAY TRENDS 66

Cytogenetic Analysis (Continued) 67

TABLE 30 FUTURE TECHNOLOGY NEEDS FOR CGH MICROARRAYS 68

miRNA Analysis 69

TABLE 31 WORKFLOW FOR AN MIRNA EXPERIMENT 70

TABLE 32 TECHNICAL CHALLENGES FOR MIRNAS 71

ARRAYS ON BEADS 72

TABLE 33 ARRAYS ON BEADS VERSUS PLANAR MICROARRAYS 72

CATALOG AND CUSTOM DNA MICROARRAYS 72

SUPPLY OF REAGENTS AND SAMPLE PREPARATION FOR MICROARRAYS 73

TOXICOGENOMICS 74

DNA SEQUENCING 75

FIGURE 15 COMPARISON OF SANGER WITH UHTS DNA SEQUENCING TECHNOLOGIES 76

TABLE 34 SMS TECHNOLOGY 77

TABLE 35 COMPARISON OF SELECTED DNA SEQUENCING PLATFORMS 78

FIGURE 16 COMPETITIVE SPACE FOR HIGH-THROUGHPUT GENOMIC ANALYSIS 79

TABLE 36 BIOCHIP CONTENT IN NHGRI GRANTEES FOR NEXT-GENERATION DNA SEQUENCING, 2005 80

TABLE 36 (CONTINUED) 81

TABLE 37 NEXT-GENERATION DNA SEQUENCING COMPANIES 82

RESEQUENCING APPROACHES IN DIAGNOSTICS 82

DNA MICROARRAY MANUFACTURING 83

FIGURE 17 DNA MICROARRAY MANUFACTURING TECHNOLOGIES 83

DNA Microarray Manufacturing (Continued) 84

TABLE 38 DNA MICROARRAY PROBE DENSITY TRENDS, FEATURES PER CHIP, 1996-2009 85

DNA MICROARRAY TECHNOLOGY TRENDS 85

DNA MICROARRAY TECHNOLOGY CHALLENGES 86

FIGURE 18 DNA MICROARRAY COST-VOLUME CURVE 87

PROTEIN MICROARRAY TECHNOLOGIES 88

INTRODUCTION 88

FIGURE 19 IMPORTANCE OF PROTEINS 88

PROTEOMICS WORKFLOW 89

FIGURE 20 PROTEIN ANALYSIS APPROACHES CONTRASTED 89

PROTEIN MICROARRAY DESIGN FEATURES 90

TABLE 39 PROTEIN MICROARRAY PLATFORMS 90

PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS 91

TABLE 40 PROTEIN MICROARRAYS AS RESEARCH TOOLS 92

PROTEIN MICROARRAY TYPES 93

TABLE 41 PROTEIN MICROARRAY PRODUCT TYPES 93

Protein Microarray Types (Continued) 94

PROTEIN MICROARRAY TECHNOLOGY CHALLENGES 95

TABLE 42 PROTEIN MICROARRAY TECHNICAL CHALLENGES 96

Protein Microarray Technology Challenges (Continued) 97

PROTEIN MICROARRAY TECHNOLOGY TRENDS 98

TABLE 43 PROTEIN MICROARRAY TECHNOLOGY TRENDS 98

EMERGING MICROARRAY TECHNOLOGIES 99

TABLE 44 EMERGING MICROARRAY TECHNOLOGIES 99

GLYCOMICS MICROARRAYS 100

Glycomics Microarrays (Continued) 101

TMAS 102

FCMS 103

TABLE 45 U.S. GOVERNMENT INITIATIVES PROMOTING EMERGING MICROARRAYS 104

MICROARRAY TECHNOLOGY TRENDS 105

TABLE 46 MICROARRAY TECHNOLOGY TRENDS 105

MICROARRAY TECHNOLOGY TRENDS (CONTINUED) 106

Chapter-5: LOAC TECHNOLOGIES

INTRODUCTION 107

TABLE 47 MICROFLUIDICS PRODUCT LIFE CYCLE STAGE 107

TABLE 48 LOAC SUBSTRATE TECHNOLOGIES 108

LOAC TYPES 109

TABLE 49 LOAC TYPES 109

IN VITRO PROTEOMICS 109

ELECTROPHORESIS ON A CHIP 110

STRUCTURAL PROTEOMICS 110

PCR ON A CHIP 111

IMMUNOASSAYS ON A CHIP 112

Immunoassays on a Chip (Continued) 113

TABLE 50 IMMUNOASSAY-ON-A-CHIP APPLICATIONS 114

LOAC APPLICATIONS 114

TABLE 51 LOAC MARKET SEGMENTS 115

TABLE 52 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS 116

LOAC KEY TECHNOLOGY TRENDS 116

TABLE 53 LOAC KEY TECHNOLOGY TRENDS 117

TABLE 54 LOAC TECHNOLOGY PLATFORMS 118

LOAC TECHNOLOGY CHALLENGES 119

TABLE 55 LOAC TECHNOLOGY CHALLENGES 120

Chapter-6: BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT

BIOCHIP MARKET SEGMENTATION 121

TABLE 56 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS 121

DRUG DISCOVERY AND DEVELOPMENT 122

TABLE 57 DRUG R&D INVESTMENT BY STAGE, 2003 (%) 123

DRUG INDUSTRY CHALLENGES 123

OVERVIEW OF THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 124

FIGURE 21 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE 124

TABLE 58 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 125

TABLE 58 (CONTINUED) 126

DRUG TARGET IDENTIFICATION 127

DRUG DISCOVERY 127

Structural Biology 127

Lead Generation 128

Lead Generation (Continued) 129

Lead Generation (Continued) 130

Lead Optimization 131

Process R&D 132

Preclinical and Clinical Trials 132

NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 132

TABLE 59 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 132

TABLE 59 (CONTINUED) 133

Needs in the Drug Discovery and ... (Continued) 133

Needs in the Drug Discovery and ... (Continued) 134

FIGURE 22 VALIDATION GAP FOR FUTURE DRUG TARGETS (NUMBER OF POTENTIAL DRUG TARGETS) 135

Needs in the Drug Discovery and ... (Continued) 136

Chapter-7: BIOCHIP APPLICATIONS IN DIAGNOSTICS

INTRODUCTION 137

DRIVING FORCES FOR ADOPTION OF BIOCHIP DIAGNOSTIC PLATFORMS 137

BIOMARKER DISCOVERY AND VALIDATION 137

CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS 138

TABLE 60 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS 139

MICROARRAY STANDARDIZATION EFFORTS 140

Microarray Quality Control Project 140

External RNA Controls Consortium (ERCC) Study 141

Association of Bimolecular Resource Facilities (ABRF) CGH Microarray Platform Study 142

TABLE 61 COMPARISON OF ARRAY-CGH PLATFORMS 142

OVERVIEW OF MDX 143

INTRODUCTION 143

BENEFITS OF BIOCHIPS AS AN MDX PLATFORM 144

Benefits of Biochips as an MDx Platform (Continued) 145

FIGURE 23 BIOCHIPS TARGET HIGH GROWTH, HIGH MARGIN PORTION OF THE IVD MARKET 146

TABLE 62 BIOTECHNOLOGY DRUGS APPROVED BY THE FDA, 1980-2008 (NUMBER) 147

PHARMACOGENOMICS TESTS 147

Pharmacogenomics Tests (Continued) 148

STRATEGIES FOR COMMERCIALIZING PGX TESTS 149

MDX MARKET PENETRATION CHALLENGES 150

TABLE 63 COMPARISON OF DNA-BASED MDX PLATFORMS 151

TABLE 64 FACTORS AFFECTING PENETRATION OF BIOCHIPS INTO THE MDX MARKET 152

MDX Market Penetration Challenges (Continued) 153

MDX MARKET SEGMENTS 154

MDX TEST SENSITIVITY AND SPECIFICITY 155

FIGURE 24 SENSITIVITY AND SPECIFICITY 156

STATUS OF BIOCHIPS DIAGNOSTICS BY INDICATION 157

SUMMARY OF BIOCHIPS DIAGNOSTICS 157

CANCER OVERVIEW 157

TABLE 65 U.S. INCIDENCE AND TREATMENT DECISIONS FOR SELECTED CANCERS, 2009 157

HEMATOLOGICAL CANCERS 158

BLADDER CANCER 158

BREAST CANCER 159

Breast Cancer Screening 159

Prognosis and Pharmacogenetics Tests 160

FIGURE 25 BREAST CANCER TREATMENT DECISION TREE FOR ONCOTYPE DX 161

TABLE 66 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION 162

Breast Cancer MDx Platforms 162

TABLE 67 BREAST CANCER MDX TECHNOLOGY PLATFORMS 163

Breast Cancer Multivariate Diagnostic Tests 164

TABLE 68 COMMERCIAL LANDSCAPE FOR MULTIVARIATE BREAST CANCER TESTS, BY PARAMETER 164

TABLE 68 (CONTINUED) 165

Breast Cancer Multivariate ... (Continued) 166

Regulatory Status of Gene Profiling Diagnostic Tests 167

TABLE 69 FDA REGULATORY POSITION ON IVDMIA 167

CERVICAL CANCER 168

TABLE 70 COMMERCIAL LANDSCAPE FOR HPV TESTS 168

TABLE 70 (CONTINUED) 169

COLORECTAL CANCER 170

Conventional Colorectal Cancer Screening Tests 170

TABLE 71 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL CANCER 171

Molecular Colorectal Cancer Diagnostics Tests 172

TABLE 72 COMMERCIAL LANDSCAPE FOR COLORECTAL MOLECULAR TESTS 172

Molecular Colorectal Cancer ... (Continued) 173

CUP 174

TABLE 73 COMMERCIAL MDX PLATFORMS FOR TISSUE OF ORIGIN TESTS 175

GASTRIC CANCER 176

LUNG CANCER 177

Lung Cancer (Continued) 178

OVARIAN CANCER 179

TABLE 74 OVARIAN CANCER SCREENING TESTS 179

TABLE 75 OVARIAN CANCER DIAGNOSTIC TEST STATUS 180

PANCREATIC CANCER 180

PEDIATRIC CANCERS 181

PROSTATE CANCER 181

Prostate Cancer (Continued) 182

COMPREHENSIVE CANCER TESTS 183

STATUS OF BIOCHIP-BASED INFECTIOUS DISEASE DIAGNOSTICS 183

SEPSIS 183

TUBERCULOSIS 184

MRSA 184

INFLUENZA 185

OTHER INFECTIOUS DISEASES 185

STATUS OF BIOCHIP-BASED DME DIAGNOSTICS 186

DMES 186

TABLE 76 MICROARRAY-BASED DME DIAGNOSTICS TESTS 186

DMEs (Continued) 187

WARFARIN DOSING 188

TABLE 77 WARFARIN CYP PGX DIAGNOSTICS TEST COMPETITOR SPACE 189

TABLE 77 (CONTINUED) 190

Warfarin Dosing (Continued) 191

TABLE 78 CYP450 GENE FAMILY PHARMACOGENETIC DIAGNOSTIC GLOBAL TEST MARKET POTENTIAL, 2009 ($ MILLIONS) 192

STATUS OF BIOCHIP-BASED NEUROLOGICAL DIAGNOSTICS 192

ALZHEIMER'S DISEASE 192

SCHIZOPHRENIA 193

STATUS OF BIOCHIP-BASED HEART DISEASE DIAGNOSTICS 193

CHF FAILURE 193

TABLE 79 BNP MDX TESTS FOR CHF 194

CHF Failure (Continued) 195

OTHER CARDIAC DIAGNOSTICS 196

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR CF 197

TABLE 80 CF BIOCHIP DIAGNOSTIC PLATFORMS 197

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR PRE- AND POST-NATAL 198

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR IMMUNE DISEASES 199

HLA TYPING TESTS 199

AUTOIMMUNE TESTING 200

STATUS OF BIOCHIP-BASED DIAGNOSTICS FOR FOOD SAFETY/QC 201

TABLE 81 BIOCHIPS STATUS IN FOOD SAFETY/QC MARKET 201

STATUS OF BIOCHIP- ... (CONTINUED) 202

Chapter-8: BIOCHIP MARKET GROWTH DRIVING FORCES

INTRODUCTION 203

FIGURE 26 GROWTH IN SCIENTIFIC PUBLICATIONS RELATED TO MICROARRAYS AND LAB ON A CHIP, 2000-2009 (NUMBER OF PUBMED CITATIONS) 203

FIGURE 26 (CONTINUED) 204

BIOCHIP GROWTH DRIVING FORCES 204

TABLE 82 PRIMARY FORCES DRIVING OVERALL BIOCHIPS GROWTH 205

FUNDING FOR LIFE SCIENCE RESEARCH 205

TABLE 83 STIMULUS FUNDING ALLOCATED TO U.S. SCIENCE SPENDING, 2009 ($ MILLIONS) 206

FIGURE 27 NIH ANNUAL FUNDING BUDGET, 2000-2009 ($ BILLIONS) 206

LARGE-SCALE GENOMIC, PROTEOMIC, AND BIOCHIP INITIATIVES 207

TABLE 84 RESEARCH INITIATIVES DRIVING BIOCHIP GROWTH, 1999-2008 208

Large-scale Genomic, Proteomic, ... (continued) 209

NEED FOR MORE EFFICIENT DRUG DISCOVERY AND DEVELOPMENT PROCESS 210

GROWTH IN PERSONALIZED MEDICINE 210

NEED FOR EARLY DETECTION OF CANCERS 211

AGING POPULATIONS 211

NEW DISCOVERIES IN GENOMICS AND PROTEOMICS 212

MINIATURIZATION OF BIOCHIPS 212

DECLINE IN GENETIC ANALYSIS COSTS 212

DISCOVERY OF GENE- AND SNP-DISEASE ASSOCIATIONS 213

Chapter-9: BIOCHIP MARKETS

GLOBAL BIOCHIP MARKET 214

TABLE 85 GLOBAL VALUE OF BIOCHIP PRODUCTS BY TYPE, THROUGH 2014 ($ MILLIONS) 214

TABLE 86 GLOBAL VALUE OF BIOCHIP MARKET BY END USE, THROUGH 2014 ($ MILLIONS) 215

MICROARRAY MARKETS 216

TABLE 87 GLOBAL VALUE OF MICROARRAYS BY TYPE, THROUGH 2014 ($ MILLIONS) 216

DNA MICROARRAY MARKETS 217

DNA MICROARRAY MARKET BY APPLICATION 217

TABLE 88 GLOBAL VALUE OF DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 217

DNA Microarray Market by Application (Continued) 218

FIGURE 28 ENTRIES TO MIRNA DATABASE, 2002-2009 (NUMBER) 219

TABLE 89 GLOBAL VALUE OF GENOTYPING DNA MICROARRAYS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 220

DNA MICROARRAY MARKET BY END-USE INDUSTRY 220

TABLE 90 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS) 221

DNA MICROARRAY MARKET BY FORMAT 222

TABLE 91 GLOBAL VALUE OF DNA MICROARRAYS BY FORMAT, THROUGH 2014 ($ MILLIONS) 222

BIOCHIPS DIAGNOSTICS MARKETS 223

BIOCHIPS DIAGNOSTIC MARKET BY APPLICATION 223

TABLE 92 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY APPLICATION, THROUGH 2014 ($ MILLIONS) 224

Biochips Diagnostic Market by Application (Continued) 225

BIOCHIP DIAGNOSTICS MARKET BY BIOCHIP TYPE 226

TABLE 93 GLOBAL VALUE OF DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS) 226

CANCER DIAGNOSTICS BIOCHIPS MARKET BY INDICATION 227

TABLE 94 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY INDICATION, THROUGH 2014 ($ MILLIONS) 227

Cancer Diagnostics Biochips Market ... (Continued) 228

CANCER DIAGNOSTICS BIOCHIPS MARKET BY BIOCHIP TYPE 229

TABLE 95 GLOBAL VALUE OF CANCER DIAGNOSTIC BIOCHIPS BY TYPE, THROUGH 2014 ($ MILLIONS) 229

TABLE 96 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS 230

DIAGNOSTIC DNA MICROARRAYS MARKET BY ANALYSIS METHOD 231

TABLE 97 GLOBAL VALUE OF DIAGNOSTIC DNA MICROARRAYS BY ANALYSIS METHOD, THROUGH 2014 ($ MILLIONS) 231

Diagnostic DNA Microarrays Market ... (Continued) 232

DIAGNOSTIC DNA MICROARRAYS MARKET BY DIAGNOSTIC FUNCTION 233

TABLE 98 GLOBAL VALUE OF DNA MICROARRAYS DIAGNOSTICS BY DIAGNOSTIC FUNCTION, THROUGH 2014 ($ MILLIONS) 233

DIAGNOSTIC PROTEIN MICROARRAY MARKET BY TECHNOLOGY 234

TABLE 99 GLOBAL VALUE OF PROTEIN MICROARRAY DIAGNOSTICS MARKET BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 235

PROTEIN MICROARRAYS MARKETS 236

PROTEIN MICROARRAYS MARKETS BY TECHNOLOGY 236

TABLE 100 GLOBAL VALUE OF PROTEIN MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 236

Protein Microarrays Markets by Technology (Continued) 237

PROTEIN MICROARRAYS MARKET BY PRODUCT FORMAT 238

TABLE 101 GLOBAL VALUE OF PROTEIN MICROARRAYS BY PRODUCT FORMAT, THROUGH 2014 ($ MILLIONS) 238

TABLE 102 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS 239

PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY 240

TABLE 103 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH 2014 ($ MILLIONS) 240

EMERGING MICROARRAYS MARKETS 241

EMERGING MICROARRAYS MARKET BY TECHNOLOGY 241

TABLE 104 GLOBAL VALUE OF EMERGING MICROARRAYS BY TECHNOLOGY, THROUGH 2014 ($ MILLIONS) 241

EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY 242

TABLE 105 GLOBAL VALUE OF EMERGING MICROARRAYS BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS) 243

LOAC MARKETS 243

VALUE OF LOAC DEVICES BY END-USE INDUSTRY 243

TABLE 106 GLOBAL VALUE OF LOAC DEVICES BY END-USE INDUSTRY, THROUGH 2014 ($ MILLIONS) 244

Value of LOAC Devices by End-Use Industry (Continued) 245

Value of LOAC Devices by End-Use Industry (Continued) 246

Value of LOAC Devices by End-Use Industry (Continued) 247

LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION 248

TABLE 107 GLOBAL VALUE OF LOAC DRUG DISCOVERY AND DEVELOPMENT MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS) 249

LOAC Drug Discovery and Development ... (Continued) 250

LOAC DIAGNOSTICS MARKET BY APPLICATION 251

TABLE 108 GLOBAL VALUE OF LOAC DEVICES DIAGNOSTICS MARKET BY APPLICATION, THROUGH 2014 ($ MILLIONS) 252

LOAC Diagnostics Market by Application (Continued) 253

BIOCHIPS GEOGRAPHIC MARKETS 254

GLOBAL VALUE OF BIOCHIPS PRODUCTS BY GEOGRAPHY 254

TABLE 109 GLOBAL VALUE OF BIOCHIP PRODUCTS BY GEOGRAPHY, THROUGH 2014 ($ MILLIONS) 255

MICROARRAY GEOGRAPHICAL MARKETS 255

TABLE 110 GLOBAL VALUE OF DNA MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 256

TABLE 111 GLOBAL VALUE OF PROTEIN MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 257

TABLE 112 GLOBAL VALUE OF EMERGING MICROARRAYS BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 257

LOAC GEOGRAPHICAL MARKETS 258

TABLE 113 GLOBAL VALUE OF LOAC BY GEOGRAPHIC REGION, THROUGH 2014 ($ MILLIONS) 258

Chapter-10: INDUSTRY DYNAMICS

INTRODUCTION 259

RECENT ACQUISITIONS IN THE BIOCHIP INDUSTRY 259

TABLE 114 KEY ACQUISITIONS IN BIOCHIP INDUSTRY, 2007-2009 260

RECENT ACQUISITIONS IN THE BIOCHIP ... (CONTINUED) 261

RECENT ACQUISITIONS IN THE BIOCHIP ... (CONTINUED) 262

RECENT ACQUISITIONS IN THE BIOCHIP ... (CONTINUED) 263

DNA MICROARRAYS COMPETITIVE LANDSCAPE 264

TABLE 115 LEADING DNA MICROARRAY SUPPLIERS 264

TABLE 115 (CONTINUED) 265

SOURCES OF COMPETITIVE ADVANTAGE IN DNA MICROARRAYS 265

SOURCES OF COMPETITIVE ... (CONTINUED) 266

TABLE 116 DNA MICROARRAY AND SEQUENCING COMPETITOR STRENGTHS AND WEAKNESSES 267

NEXT GENERATION SEQUENCING COMPETITIVE LANDSCAPE 268

TABLE 117 NUMBER OF SECOND-GENERATION GENOME SEQUENCING INSTRUMENTS AT MAJOR SEQUENCING CENTERS, 2009 269

DIAGNOSTICS BIOCHIP STRATEGIC ALLIANCES 269

TABLE 118 BIOCHIP STRATEGIC ALLIANCES IN DIAGNOSTICS 270

DIAGNOSTICS BIOCHIP STRATEGIC ... (CONTINUED) 271

PROTEIN MICROARRAY SUPPLIERS 272

TABLE 119 PROTEIN AND SPECIALTY MICROARRAY SUPPLIERS BY MICROARRAY TECHNOLOGY 272

LOAC COMPETITIVE LANDSCAPE 273

TABLE 120 LOAC COMPETITOR LANDSCAPE, BY COMPANY 273

TABLE 120 (CONTINUED) 274

TABLE 120 (CONTINUED) 275

Chapter-11: PATENTS

INTRODUCTION 276

BIOCHIP INDUSTRY PATENT STATUS 276

FIGURE 29 ANNUAL ISSUED DNA MICROARRAY PATENTS BY REGION, 2001-2009 (NUMBER) 277

FIGURE 30 ANNUAL ISSUED PROTEIN MICROARRAY PATENTS BY REGION, 2001-2009 (NUMBER OF PATENTS GRANTED) 278

FIGURE 31 ANNUAL ISSUED LOAC PATENTS BY GEOGRAPHY, 2001-2009 (NUMBER) 279

BIOCHIP COMPANY PATENT STATUS 280

TABLE 121 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED MICROARRAY COMPANIES (NUMBER) 280

FIGURE 32 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED MICROARRAY COMPANIES, BY REGION (NUMBER) 281

FIGURE 32 (CONTINUED) 282

TABLE 122 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED LOAC COMPANIES (NUMBER) 283

FIGURE 33 ISSUED PATENTS AND PATENT APPLICATIONS FOR SELECTED LOAC COMPANIES (NUMBER) 284

BIOCHIP PATENT LITIGATION STATUS 284

TABLE 123 STATUS OF LITIGATION ISSUES IN THE BIOCHIP INDUSTRY 285

INDIVIDUAL PATENT STATUS OF SELECTED BIOCHIP COMPANIES 285

AFFYMETRIX POSITION 285

COMBIMATRIX POSITION 286

ILLUMINA POSITION 287

CALIPER POSITION 287

ROCHE-NIMBLEGEN POSITION 288

Chapter-12: COMPANY PROFILES

20/20 GENE SYSTEMS, INC. 289

ABBOTT LABORATORIES 290

ABTECH SCIENTIFIC, INC. 290

ADVANCED LIQUID LOGIC, INC. 291

AFFYMETRIX, INC. 292

AFFYMETRIX, INC. (CONTINUED) 293

TABLE 124 AFFYMETRIX STRATEGIC ALLIANCES 294

AFFYMETRIX, INC. (CONTINUED) 295

AGENDIA BV 296

TABLE 125 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE 296

AGENDIA BV (CONTINUED) 297

AGILENT TECHNOLOGIES, INC. 298

AGILENT TECHNOLOGIES, INC. (CONTINUED) 299

TABLE 126 AGILENT ACQUISITIONS, 2007-2009 300

AGNITIO SCIENCE AND TECHNOLOGY 301

ALLEGRO DIAGNOSTICS, INC. 302

ALMAC GROUP, LTD. 302

APPLIED MICROARRAYS, INC. 303

APPLIED MICROARRAYS, INC. (CONTINUED) 304

ARRAYIT CORP. 305

ARRAYJET, LTD. 305

ARRAYON BIOTECHNOLOGY 306

ASPER BIOTECH 306

ASTERAND 306

AUSHON BIOSYSTEMS, INC. 307

AUTOGENOMICS, INC. 307

TABLE 127 AUTOGENOMICS MICROARRAY-BASED DIAGNOSTICS PIPELINE 308

AYANDA BIOSYSTEMS S.A. 308

BAYER AG 309

TABLE 128 CELL LYSATE MICROARRAYS VERSUS WESTERN BLOT 310

BECTON DICKINSON 311

BIACORE AB 311

BIOCARTIS S.A. 312

BIODOT, INC. 312

BIOLOC, LLC 312

BIOMICRO SYSTEMS, INC. 313

BIO-RAD LABORATORIES, INC. 313

BIOSITE, INC. 314

BIOTHERANOSTICS 315

BIOTRAY 315

BIOTROVE, INC. 316

BLUEGNOME, LTD. 316

BODITECH MED, INC. 317

CALIPER LIFE SCIENCES 317

CALIPER LIFE SCIENCES (CONTINUED) 318

CALIPER LIFE SCIENCES (CONTINUED) 319

CAPITALBIO CORP. 320

CAPITALBIO CORP. (CONTINUED) 321

CELLECTRICON AB 322

CELLIX, LTD. 322

CELL-KINETICS, LTD. 323

CEPHEID 324

TABLE 129 COMMERCIAL STATUS OF CEPHEID CLINICAL DIAGNOSTIC TESTS BASED ON XPERT AND SMARTCYCLER PLATFORMS 325

CEPHEID (CONTINUED) 326

CLAROS DIAGNOSTICS 327

CLONTECH LABORATORIES 328

COMBIMATRIX CORP. 329

TABLE 130 COMBIMATRIX DNA MICROARRAY PLATFORMS 329

TABLE 131 COMBIMATRIX DNA MICROARRAY-BASED LAUNCHED DIAGNOSTICS 330

COVENTOR, INC. 331

CRYSTAL VISION MICROSYSTEMS S.A. 331

CYCLOFLUIDIC 332

DEBIOTECH S.A. 332

DIAGENIC ASA 332

DIAGENIC ASA (CONTINUED) 333

TABLE 132 DIAGENIC PATENT PORTFOLIO 334

DIAGNOSWISS S.A. 334

DNAVISION S.A. 335

DYCONEX AG 336

ECOARRAY, INC. 337

EDEL THERAPEUTICS S.A. 337

EKSIGENT TECHNOLOGIES 338

EPIGEM, LTD. 338

EXIQON A/S 339

EXONHIT THERAPEUTICS S.A. 340

TABLE 133 EXONHIT'S SPLICE-ARRAY DIAGNOSTICS PIPELINE 340

EXONHIT THERAPEUTICS S.A. (CONTINUED) 341

FEBIT BIOTECH GMBH 342

FLUIDIGM CORP. 342

FLUIDIGM CORP. (CONTINUED) 343

FLUIGENT 344

FLUXION BIOSCIENCES INC. 344

GE HEALTHCARE LIFE SCIENCES, LTD. 344

GENETIX, LTD. 345

GENEWAVE S.A.S. 346

GENOMICS USA, INC. 347

GENPROBE, INC. 347

GENTEL BIOSCIENCES, INC. 348

GLYCOMINDS, LTD. 349

GRACE BIO-LABS, INC. 349

GREINER BIO-ONE GMBH 350

TABLE 134 GREINER BIO-ONE BIOCHIP-BASED DIAGNOSTICS PIPELINE 350

GYROS AB 351

HANDYLAB, INC. 352

HIGH THROUGHPUT GENOMICS, INC. 353

HOLOGIC, INC. 353

IBIDI GMBH 354

ICX TECHNOLOGIES 354

ILLUMINA, INC. 355

TABLE 135 ILLUMINA SEQUENCING TECHNOLOGY SPACE 356

IMMUCOR, INC. 357

INDEVR, INC. 358

INVERNESS MEDICAL INNOVATIONS, INC. 358

IRIS BIOTECHNOLOGIES 359

JOHNSON & JOHNSON AMIC AB 360

KINEXUS BIOINFORMATICS CORP. 361

LC SCIENCES 361

LIFE BIOSCIENCE, INC. 362

LIFE TECHNOLOGIES, INC. 363

LIFE TECHNOLOGIES, INC. (CONTINUED) 364

LUMINEX 365

TABLE 136 LUMINEX MDX PIPELINE 366

TABLE 137 LUMINEX PARTNER SUMMARY 367

MICRALYNE, INC. 368

MICROCHIPS, INC. 368

MICROFLUIDIC SYSTEMS, INC. 369

MICROLIQUID 370

MICRONICS, INC. 370

MICRONIT MICROFLUIDICS 371

MICROPLUMBERS MICROSCIENCES, LLC 371

MILLIPORE 372

MOBIDIAG, LTD. 372

MOLECULAR PROFILING INSTITUTE 373

NANOSPHERE 374

NANOSURFACE BIOSCIENCES 374

NUVERA BIOSCIENCES 375

OCIMUM BIOSOLUTIONS, LTD. 376

ORIGENE TECHNOLOGIES, INC. 376

OSMETECH MOLECULAR DIAGNOSTICS 377

OSMETECH MOLECULAR DIAGNOSTICS (CONTINUED) 378

OY JURILAB, LTD. 379

PAMGENE INTERNATIONAL B.V. 380

PANAGENE, INC. 380

PATHWORK DIAGNOSTICS 381

PEPSCAN PRESTO B.V. 382

PERKINELMER 382

PERKINELMER (CONTINUED) 383

PERLEGEN SCIENCES, INC. 384

PROMEGA CORP. 384

PROTAGEN AG 385

QUANTRX BIOMEDICAL CORP. 386

QUEST DIAGNOSTICS 387

RANDOX LABORATORIES, LTD. 388

TABLE 138 RANDOX BIOCHIPS ASSAYS PORTFOLIO 389

ROCHE LIFE SCIENCES 390

ROCHE LIFE SCIENCES (CONTINUED) 391

SEQUENOM, INC. 392

SEQUENOM, INC. (CONTINUED) 393

SCHOTT JENA GLASS GMBH 394

SIEMENS AG 395

SIGMA ALDRICH CORP. 395

TABLE 139 SIGMA ALDRICH ACQUISITIONS, 2006-2009 396

SIGNATURE GENOMIC LABORATORIES, LLC 397

SIRS-LAB GMBH 398

SPINX TECHNOLOGIES 398

SQI DIAGNOSTIC SYSTEMS 399

STMICROELECTRONICS 400

SUPERBIOCHIP LABORATORIES 401

SURMODICS, INC. 401

TESSARAE 402

THINXXS MICROTECHNOLOGY AG 402

TRANSLUME, INC. 403

VEREDUS LABORATORIES PTE, LTD. 403

VERENIUM CORP. 404

WASATCH MICROFLUIDICS 405

WEIDMAN PLASTICS TECHNOLOGIES 405

WETWARE CONCEPTS S.R.L. 406

XCEED MOLECULAR 406

XENOPORE 407

ZEPTOSENS AG 407

ZEPTOSENS AG (CONTINUED) 408

To order this report:

Biotechnology Industry: Global Biochip Markets: Microarrays and Lab-on-a-Chip

More Market Research Report


    Contact Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com